Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Metabolic vulnerabilities in CML & the impact of TKIs on glucose anaplerosis

Kevin Rattigan • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Kevin Rattigan, PhD, University of Glasgow, Glasgow, UK, comments on the differences in metabolism between leukemic stem cells and their normal counterparts, highlighting the results of a study examinating the impact of tyrosine kinase inhibition on glucose anaplerosis, explaining how this may help developing novel treatment approaches in chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals